Entrada Therapeutics (TRDA) Operating Leases (2022 - 2026)

Entrada Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $45.5 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 9.94% year-over-year to $45.5 million in Q1 2026; TTM through Mar 2026 was $45.5 million, a 9.94% decrease from a year earlier, with the FY2025 full-year figure at $46.8 million, down 9.4% from the prior year.
• Operating Leases slipped to $45.5 million in Q1 2026 per TRDA's latest filing, from $46.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $73.0 million in Q2 2023 and bottomed at $16.2 million in Q1 2023.
• The 5-year median for Operating Leases is $49.3 million (2025), against an average of $45.7 million.
• Across the five-year window, Operating Leases tumbled 49.07% in 2023 and jumped 258.28% in 2024, its largest moves.
• Year by year, Operating Leases stood at $17.5 million in 2022, then surged by 244.1% to $60.3 million in 2023, then declined by 14.38% to $51.6 million in 2024, then declined by 9.4% to $46.8 million in 2025, then fell by 2.83% to $45.5 million in 2026.
• Per Business Quant, the three latest TRDA Operating Leases figures stand at $45.5 million (Q1 2026), $46.8 million (Q4 2025), and $48.0 million (Q3 2025).